Alcon Inc Stock Price, News & Analysis

Alcon (ALC) reported strong Q3 2024 results with sales of $2.4 billion, up 6% year-over-year. The company achieved diluted EPS of $0.53, a 29% increase, and core diluted EPS of $0.81, up 23%. Notable performance includes record free cash flow of $1.3 billion, up 119% in the first nine months. Surgical segment sales reached $1.3 billion (+5%), while Vision Care segment hit $1.1 billion (+7%). The company generated $1.6 billion in operating cash flows and updated its 2024 outlook, projecting net sales between $9.8-9.9 billion with core diluted EPS of $3.00-3.05.

Alcon (ALC) has launched PRECISION7, a revolutionary one-week replacement contact lens in the U.S. The lens features the world's first ACTIV-FLO System, providing 16 hours of comfort and precise vision through day 7. This innovation addresses affordability concerns, as over half of new patients opt for reusable lenses despite ECPs preferring daily disposables. PRECISION7 will be available through select ECPs immediately, with broader U.S. commercial availability in January 2025. The product launches with both sphere and toric lenses simultaneously, featuring a unique moisturizing system that combines water-loving agents and proprietary replenishing technology.

Alcon Singapore has been recognized as one of the 'Best Employers in Singapore' for three years (2021, 2023, and 2024), achieving second place in the Health Care Equipment & Services Industry category. The recognition comes from a comprehensive survey by The Straits Times, where associates anonymously evaluate their willingness to recommend their company. Alcon Singapore focuses on three key areas: Diversity & Inclusion, Social Impact and Sustainability, and Talent Development. The company implements various programs including the 'Women Supporting Women' initiative, community engagement through 'Alcon in Action', and the upgraded 'Development In Action' program for associate growth.

Alcon (SIX/NYSE: ALC) will showcase its latest innovations at the American Academy of Ophthalmology (AAO) 2024 annual meeting. Key highlights include:

• The Voyager DSLT, a new first-line laser therapy for glaucoma patients
• New handheld gas delivery systems, UNIFEYE and UNIPEXY, for retina surgeons
• Pivotal data presentation for AR-15512 (acoltremon 0.003%), a dry eye treatment candidate under FDA review

Alcon's booth #4008 will offer hands-on demonstrations of these technologies. The company emphasizes its focus on improving patient outcomes and enhancing surgical efficiency. New clinical data on Alcon's surgical products will also be presented at the conference.

Horizon Sports & Experiences (HS&E) has announced Shark Beauty™ as the title sponsor for the inaugural Shark Beauty™ Women's Champions Classic, a primetime women's college basketball showcase. The event, scheduled for December 7 at Barclays Center in Brooklyn, will feature the University of Connecticut, University of Iowa, University of Louisville, and University of Tennessee in a doubleheader broadcast on FOX.

This collaboration between HS&E and FOX Sports marks a significant step in elevating women's college basketball. Shark Beauty™ will receive broadcast and digital integrations, sponsorship elements, hospitality, fan engagement activation, and in-arena signage as part of its multiyear partnership. The event aims to provide a national spotlight for women's basketball and introduce Shark Beauty to a wide audience of passionate fans.

Alcon (ALC) reported strong Q2 2024 results with record sales of $2.5 billion, up 3% (6% constant currency). Key highlights include:

- Diluted EPS of $0.45, up 32% (47% cc)
- Core diluted EPS of $0.74, up 7% (15% cc)
- H1 2024 cash from operations of $871 million
- Free cash flow of $667 million, up 253%

Growth was driven by robust demand for innovative products, balanced geographic footprint, and strong execution. Surgical sales increased 3% (6% cc) to $1.4 billion, with strength in international markets. Vision Care sales grew 4% (6% cc) to $1.1 billion, led by contact lenses. The company maintained its 2024 outlook, projecting 7-9% constant currency sales growth and core diluted EPS of $3.00-$3.10.

Alcon announced that its Unity Vitreoretinal Cataract System (VCS) and Unity Cataract System (CS) have received U.S. FDA 510(k) clearance. These systems are the first innovations from Alcon's Unity portfolio, aimed at transforming surgical procedures in ophthalmology. Alcon plans to gather real-world user feedback in the U.S. before a broad commercialization in 2025. The Unity systems are set to replace Alcon's current leading systems and introduce significant workflow efficiencies. Regulatory submissions will continue globally, with a CE Mark expected in early 2025.

Alcon reported strong first-quarter 2024 financial results, with sales reaching $2.4 billion, a 5% increase (7% constant currency). Diluted EPS rose 43% to $0.50, while core diluted EPS improved by 11% to $0.78. The company saw significant growth in its Surgical and Vision Care segments, particularly in innovative contact lenses, which achieved record sales. Operating income rose to $368 million, with a 15.1% operating margin. Cash from operations jumped to $341 million, with free cash flow at $229 million, a $248 million year-over-year increase. A dividend of CHF 0.24 per share was approved. The company's 2024 outlook remains optimistic, maintaining sales and core EPS guidance.

Alcon Inc. announced the successful approval of all proposed resolutions at its 2024 Annual General Meeting. This includes the approval of a dividend of CHF 0.24 per share, re-election of F. Michael Ball as Chair of the Board of Directors, approval of the Board and Executive Committee compensation, and acceptance of financial reports. Shareholders also re-elected other members of the Board and committees, granted discharge to Board and Executive Committee members, and re-elected auditors.